Clinical Trial Update: Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia [Phase 2, Phase 3]

View source ↗

Summary

Romiplostim (AMG531) is being studied in Phase 2 and Phase 3 trials for aplastic anemia, and the trial is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Aplastic Anemia | Phase 2, Phase 3 | Status: COMPLETED